Autophagy was assessed by quantification of LC3 puncta after treatment with PA for 24, 48 and 72h. kinase (JNK) apoptotic pathway. In addition, osteoblasts could be safeguarded from lipotoxicity by inhibiting autophagy with the phosphoinositide kinase inhibitor 3-methyladenine or by inhibiting apoptosis with the JNK inhibitor SP600125. In summary, we have recognized two major molecular mechanisms of lipotoxicity in osteoblasts and in doing so we have recognized a new potential therapeutic approach to Rabbit polyclonal to Zyxin prevent osteoblast dysfunction and death, which are common features of age-related bone loss and osteoporosis. Keywords:Fatty acids, Apoptosis, Autophagy, Osteoporosis, Osteoblasts == Intro == Osteoporosis is definitely a major public health issue in the older population that is characterized by low bone mass, deterioration of bone microarchitecture, and improved susceptibility to fractures (Pei and Tontonoz, 2004). During the natural process of aging, bone mass declines while marrow extra fat raises (Gimble et al., 2006;Rosen and Bouxsein, 2006). In recent years, there has been increasing focus on the practical relationship between extra fat and bone (Duque, 2008;Rosen and Bouxsein, 2006) based on the idea that decreasing fat infiltration of bone may lead to an increase in bone mass (Pei and Tontonoz, 2004;Rosen and Bouxsein, 2006), which would contribute to fracture prevention. Two major therapeutic approaches to osteoporosis that target the relationship between extra fat and bone have been proposed based on the fact that extra fat and bone share not only the same precursor cell, known as the mesenchymal stem cell (MSC), but also the same microenvironment (bone marrow milieu) (Rosen and Bouxsein, 2006). The 1st approach is based on the potential for inhibition of adipogenesis to facilitate osteoblastogenesis and bone formation (Duque et al., 2013). The PHA-848125 (Milciclib) second approach is based on recentin vitroevidence for the harmful effect that adult adipocytes can have on bone, including cell dysfunction and cell death (Elbaz et al., 2010). This harmful effect is known as lipotoxicity. The approach aims to protect osteoblasts from lipotoxicity by avoiding adipocytes from secreting lipotoxic factors such as fatty acids (FA) and adipokines. Lipotoxic cell dysfunction and apoptotic cell death induced by adipocyte-secreted factors (known as lipoapoptosis) result from an overload of lipids within an organ or cells (Martino et al., 2012;Unger and Orci, 2002;Shimabukuro et al., 1998). This lipid overload, which is particularly significant in the pathology of obesity, type 2 diabetes and heart failure (Lee et al., 1994;Unger and Orci, 2002;Shimabukuro et al., 1998) entails cell dysfunction, autophagy, and activation of lipoapoptosis. The mechanisms of lipoapoptosis in organs such as heart, liver, and pancreas have been extensively analyzed (Borradaile and Schaffer, 2005;Cazanave et al., 2011;Unger and Zhou, 2001). In bone, twoin vitrostudies reported the presence of lipotoxicity after osteoblasts were exposed to adipocyte-secreted factors (Elbaz et al., 2010;Kim et al., 2008). Among these adipocyte-secreted factors, FA (mainly palmitic acid [PA]) were identified as harmful to osteoblasts; however, the intrinsic mechanisms for this lipotoxicity remain unknown. Given that autophagy and apoptosis are the most common mechanisms of lipotoxicity in additional organs and cells (Martino et al., 2012;Unger and Orci, 2002), and that apoptosis is a common feature in age-related bone loss and osteoporosis (Manolagas, 2000), we focused our analysis on identifying intrinsic mechanisms of autophagy and apoptosis in human being osteoblasts (Ob) exposed to PAin vitro. To offer a potential restorative approach to lipotoxicity in bone, we also tested whether inhibition of PA-induced autophagy and apoptosis is definitely feasible and has a beneficial effect on osteoblast survival. == Results == == PA induces cell death in Ob inside a dose-dependent manner == To examine the effect of PA on Ob survival, we performed an MTS assay in PA- and vehicle-treated cells. This homogeneous colorimetric assay determines the number of viable cells in either PA-treated or untreated conditions. Ob survival was significantly decreased PHA-848125 (Milciclib) in Ob in the presence of PA (250 and 500 M) at different time points (24, 48, 72 h) (P<0.001) (Fig. 1A). Treatment with 250 M PA resulted in 13%, 20% and 20% reduction of survival at 24, 48 and 72 h respectively. Treatment with 500 M PA resulted in 22%, 33% and 40% reduction of survival at 24, 48 and 72 h respectively. In contrast, treatment with a lower dose of PA (100 M) experienced no significant effect on cell survival compared with the vehicle-treated control. == Fig. 1. PA induces cell death in human being osteoblasts inside a dose-dependent manner. == (A) Human being osteoblasts (Ob) were treated with PA (100, 250, and 500 M) for 24, 48 and 72 h for cell survival assay (MTS). Data are mean percentage of three self-employed assays. The percentage absorbance of treated Ob was indicated relative to absorbance of PHA-848125 (Milciclib) control Ob, which was arranged at 100%. *P<0.001, vs. vehicle-treated control; #P<0.05 vs. % at 24 h for each condition. (B and C) Ob were treated with PA (100, 250 and 500 M) for 48 and 72 h..